Medicare Enrolled
Dr. Marilyn Raymond, M.D.
Medical Oncology · West Palm Beach, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Raymond from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Raymond? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Raymond
Dr. Marilyn Raymond is a medical oncology in West Palm Beach, FL, with 20 years in practice. Based on federal Medicare data, Dr. Raymond performed 40,611 Medicare services across 2,818 unique beneficiaries.
Between the years covered by Open Payments, Dr. Raymond received a total of $9,571 from 74 pharmaceutical and/or device companies across 533 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Raymond is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 37% volume in FL$ $9,571 industry payments
Medicare Practice Summary
Medicare Utilization ↗40,611
Medicare services
Top 37% in FL for medical oncology
2,818
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,031 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (aprepitant) | 11,180 | $1 | $5 |
| Filgrastim injection (Zarxio) for white blood cells | 9,540 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 4,500 | $18 | $51 |
| Contrast dye for imaging (iodine-based) | 4,340 | $0 | $1 |
| Injection, fulvestrant, 25 mg | 1,680 | $7 | $132 |
| Epoetin alfa injection (Procrit) for anemia | 1,420 | $6 | $23 |
| Dexamethasone injection (steroid) | 1,323 | $0 | $3 |
| Complete blood count (CBC) with differential | 1,223 | $8 | $29 |
| Blood draw (venipuncture) | 1,208 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 920 | $1 | $28 |
| Office visit, established patient (20-29 min) | 694 | $65 | $239 |
| Office visit, established patient (30-39 min) | 437 | $102 | $339 |
| Anti-nausea injection (ondansetron/Zofran) | 256 | $0 | $9 |
| Administration of chemotherapy into vein, 1 hour or less | 244 | $102 | $378 |
| Injection of additional new drug or substance into vein | 239 | $12 | $61 |
| Injection, zoledronic acid, 1 mg | 199 | $6 | $69 |
| Drug injection, under skin or into muscle | 172 | $11 | $69 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 156 | $25 | $89 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 144 | $23 | $84 |
| Injection, diphenhydramine hcl, up to 50 mg | 102 | $1 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 89 | $47 | $189 |
| Office visit, established patient, complex (40-54 min) | 76 | $144 | $474 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 75 | $401 | $680 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 72 | $1,166 | $3,710 |
| Administration of additional new drug or substance into vein, 1 hour or less | 64 | $52 | $178 |
| CT scan of abdomen and pelvis with contrast | 44 | $178 | $550 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 43 | $16 | $56 |
| Administration of chemotherapy into vein, each additional hour | 39 | $22 | $79 |
| Ct scan of chest with contrast | 38 | $47 | $344 |
| New patient office visit, complex (60-74 min) | 28 | $174 | $585 |
| Echocardiogram, transthoracic | 22 | $107 | $440 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $1 | $6 |
| Office visit, established patient (10-19 min) | 15 | $44 | $147 |
| CT scan of chest, without contrast | 12 | $37 | $350 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.7% high complexity
89.9% medium
9.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,571
Total received (2018-2024)
Avg $1,367/year across 7 years
Top 46% in FL for medical oncology
74
Companies
533
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,571 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,657
2023$2,371
2022$1,735
2021$940
2020$403
2019$613
2018$851
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$703
Celgene Corporation
$588
Daiichi Sankyo Inc.
$517
Incyte Corporation
$502
NanoString Technologies, Inc.
$492
Merck Sharp & Dohme LLC
$462
Novartis Pharmaceuticals Corporation
$461
AstraZeneca Pharmaceuticals LP
$384
Eisai Inc.
$339
PFIZER INC.
$327
Takeda Pharmaceuticals U.S.A., Inc.
$293
GlaxoSmithKline, LLC.
$271
Lilly USA, LLC
$262
ABBVIE INC.
$241
Ipsen Biopharmaceuticals, Inc
$239
Myriad Genetic Laboratories, Inc.
$231
Seagen Inc.
$220
Pharmacyclics LLC, An AbbVie Company
$203
Astellas Pharma US Inc
$202
GENZYME CORPORATION
$186
E.R. Squibb & Sons, L.L.C.
$155
Bayer HealthCare Pharmaceuticals Inc.
$141
Kyowa Kirin, Inc.
$126
ARRAY BIOPHARMA INC
$107
JAZZ PHARMACEUTICALS INC.
$107
Menarini Silicon Biosystems, Inc.
$98
TerSera Therapeutics LLC
$97
Amgen Inc.
$92
BeiGene USA, Inc.
$84
EMD Serono, Inc.
$72
Gilead Sciences, Inc.
$70
Pharmacyclics LLC, an AbbVie Company
$65
Alexion Pharmaceuticals, Inc.
$58
Seattle Genetics, Inc.
$57
Adaptive Biotechnologies Corporation
$55
Genentech USA, Inc.
$51
Regeneron Healthcare Solutions, Inc.
$50
Clovis Oncology, Inc.
$48
Sobi, Inc
$48
Mirati Therapeutics, Inc.
$43
Karyopharm Therapeutics Inc.
$43
Heron Therapeutics, Inc.
$43
Tempus AI, Inc
$41
Aurobindo Pharma USA, Inc.
$41
EISAI INC.
$36
Boehringer Ingelheim Pharmaceuticals, Inc.
$33
Puma Biotechnology, Inc.
$32
Merck Sharp & Dohme Corporation
$32
Bayer Healthcare Pharmaceuticals Inc.
$32
Fennec Pharmaceuticals, Inc.
$30
Dova Pharmaceuticals
$27
Aveo Pharmaceuticals, Inc.
$27
Janssen Scientific Affairs, LLC
$25
TOLMAR Pharmaceuticals, Inc.
$24
Kite Pharma, Inc.
$23
ADC Therapeutics America, Inc.
$22
Taiho Oncology, Inc.
$22
SERVIER PHARMACEUTICALS LLC
$22
TESARO, Inc.
$22
Blueprint Medicines Corporation
$20
RECORDATI_RARE_DISEASES_INC.
$20
AbbVie, Inc.
$20
Cumberland Pharmaceuticals, Inc.
$19
Deciphera Pharmaceuticals Inc.
$19
AVEO Pharmaceuticals, Inc.
$18
Sirtex Medical Inc
$18
TG THERAPEUTICS, INC.
$17
CTI BioPharma Corp.
$17
Azurity Pharmaceuticals, Inc.
$16
AbbVie Inc.
$15
Napo Pharmaceuticals Inc
$15
Stemline Therapeutics Inc.
$15
Exelixis Inc.
$11
Veracyte, Inc.
$4
Top 3 companies account for 18.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AUGTYRO · AYVAKIT · Alecensa · Aliqopa · BAVENCIO · BRAFTOVI · BRUKINSA · CABLIVI · CALQUENCE · CARVYKTI · CYRAMZA · Cabometyx · Cellsearch · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ENHERTU · EPKINLY · ERBITUX · ERLEADA · EVENITY · Enhertu · FOTIVDA · GELCLAIR CONCENTRATED ORAL GEL · GILOTRIF · HYQVIA · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · Imbruvica · JAKAFI · JEMPERLI · Jivi · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LOCAMETZ · LORBRENA · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · NERLYNX · Nerlynx · Nexavar · Nplate · Nubeqa · ONIVYDE · OPDIVO · OPDUALAG · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PRECISETUMOR · PROMACTA · PROSIGNA ASSAY · Pedmark · Perjeta · Pomalyst · Poteligeo · PreciseTumor · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rubraca · SANCUSO · SARCLISA · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUSTOL · SUTENT · SYLVANT · Stivarga · Sustol · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Tazverik · Trodelvy · UKONIQ · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VIVIMUSTA · VONVENDI · VPRIV · Venclexta · Vitrakvi · Vonjo · XALKORI · XPOVIO · XT CDX · XTANDI · Xofigo · Xospata · Yescarta · ZEJULA · ZEPZELCA · Zevalin · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $24 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
21
Per 100K population
1.4
County median income
$81,115
Nearest hospital
GOOD SAMARITAN MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Raymond is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Raymond experienced with anti-nausea injection (aprepitant)?
Based on Medicare claims data, Dr. Raymond performed 11,180 anti-nausea injection (aprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Raymond receive payments from pharmaceutical companies?
Yes. Dr. Raymond received a total of $9,571 from 74 companies across 533 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Raymond's costs compare to other medical oncologys in West Palm Beach?
Dr. Raymond's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Raymond) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in West Palm Beach
Browse medical oncologys in West Palm Beach ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology